Fragile X drug development flounders
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Nature reviews / Drug discovery - 15(2016), 2, Seite 77-77 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mullard, Asher [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.1038/nrd.2016.18 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1972260901 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1972260901 | ||
| 003 | DE-627 | ||
| 005 | 20220219183748.0 | ||
| 007 | tu | ||
| 008 | 160308s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1038/nrd.2016.18 |2 doi | |
| 028 | 5 | 2 | |a PQ20160430 |
| 035 | |a (DE-627)OLC1972260901 | ||
| 035 | |a (DE-599)GBVOLC1972260901 | ||
| 035 | |a (PRQ)c1119-b39d3c7bdda9a9291daec0915d4f030ab444d2620e0b46f05836d8101299dbab0 | ||
| 035 | |a (KEY)0473973620160000015000200077fragilexdrugdevelopmentflounders | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Mullard, Asher |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fragile X drug development flounders |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 773 | 0 | 8 | |i Enthalten in |t Nature reviews / Drug discovery |d London : Nature Publ. Group, 2001 |g 15(2016), 2, Seite 77-77 |w (DE-627)337806365 |w (DE-600)2062954-0 |w (DE-576)263021246 |x 1474-1776 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2016 |g number:2 |g pages:77-77 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1038/nrd.2016.18 |3 Volltext |
| 856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26837585 |
| 856 | 4 | 2 | |u http://search.proquest.com/docview/1766801031 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 15 |j 2016 |e 2 |h 77-77 | ||